Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Anti VEGF Market

ID: MRFR/HC/50409-HCR
200 Pages
Satyendra Maurya
Last Updated: April 24, 2026

Japan Anti-VEGF Market Research Report: Size, Share, Trend Analysis By Product (Eylea, Lucentis, Beovu) and By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Anti VEGF Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Chemicals and Materials, BY Product (USD Million)
  49.     4.1.1 Eylea
  50.     4.1.2 Lucentis
  51.     4.1.3 Beovu
  52.   4.2 Chemicals and Materials, BY Disease (USD Million)
  53.     4.2.1 Macular Edema
  54.     4.2.2 Diabetic Retinopathy
  55.     4.2.3 Retinal Vein Occlusion
  56.     4.2.4 Age-Related Macular Degeneration
  57. 5 SECTION V: COMPETITIVE ANALYSIS
  58.   5.1 Competitive Landscape
  59.     5.1.1 Overview
  60.     5.1.2 Competitive Analysis
  61.     5.1.3 Market share Analysis
  62.     5.1.4 Major Growth Strategy in the Chemicals and Materials
  63.     5.1.5 Competitive Benchmarking
  64.     5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  65.     5.1.7 Key developments and growth strategies
  66.       5.1.7.1 New Product Launch/Service Deployment
  67.       5.1.7.2 Merger & Acquisitions
  68.       5.1.7.3 Joint Ventures
  69.     5.1.8 Major Players Financial Matrix
  70.       5.1.8.1 Sales and Operating Income
  71.       5.1.8.2 Major Players R&D Expenditure. 2023
  72.   5.2 Company Profiles
  73.     5.2.1 Regeneron Pharmaceuticals (US)
  74.       5.2.1.1 Financial Overview
  75.       5.2.1.2 Products Offered
  76.       5.2.1.3 Key Developments
  77.       5.2.1.4 SWOT Analysis
  78.       5.2.1.5 Key Strategies
  79.     5.2.2 Roche (CH)
  80.       5.2.2.1 Financial Overview
  81.       5.2.2.2 Products Offered
  82.       5.2.2.3 Key Developments
  83.       5.2.2.4 SWOT Analysis
  84.       5.2.2.5 Key Strategies
  85.     5.2.3 Novartis (CH)
  86.       5.2.3.1 Financial Overview
  87.       5.2.3.2 Products Offered
  88.       5.2.3.3 Key Developments
  89.       5.2.3.4 SWOT Analysis
  90.       5.2.3.5 Key Strategies
  91.     5.2.4 Bayer (DE)
  92.       5.2.4.1 Financial Overview
  93.       5.2.4.2 Products Offered
  94.       5.2.4.3 Key Developments
  95.       5.2.4.4 SWOT Analysis
  96.       5.2.4.5 Key Strategies
  97.     5.2.5 Pfizer (US)
  98.       5.2.5.1 Financial Overview
  99.       5.2.5.2 Products Offered
  100.       5.2.5.3 Key Developments
  101.       5.2.5.4 SWOT Analysis
  102.       5.2.5.5 Key Strategies
  103.     5.2.6 Amgen (US)
  104.       5.2.6.1 Financial Overview
  105.       5.2.6.2 Products Offered
  106.       5.2.6.3 Key Developments
  107.       5.2.6.4 SWOT Analysis
  108.       5.2.6.5 Key Strategies
  109.     5.2.7 Eli Lilly (US)
  110.       5.2.7.1 Financial Overview
  111.       5.2.7.2 Products Offered
  112.       5.2.7.3 Key Developments
  113.       5.2.7.4 SWOT Analysis
  114.       5.2.7.5 Key Strategies
  115.     5.2.8 Santen Pharmaceutical (JP)
  116.       5.2.8.1 Financial Overview
  117.       5.2.8.2 Products Offered
  118.       5.2.8.3 Key Developments
  119.       5.2.8.4 SWOT Analysis
  120.       5.2.8.5 Key Strategies
  121.   5.3 Appendix
  122.     5.3.1 References
  123.     5.3.2 Related Reports
  124. 6 LIST OF FIGURES
  125.   6.1 MARKET SYNOPSIS
  126.   6.2 JAPAN MARKET ANALYSIS BY PRODUCT
  127.   6.3 JAPAN MARKET ANALYSIS BY DISEASE
  128.   6.4 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
  129.   6.5 RESEARCH PROCESS OF MRFR
  130.   6.6 DRO ANALYSIS OF CHEMICALS AND MATERIALS
  131.   6.7 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  132.   6.8 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  133.   6.9 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
  134.   6.10 CHEMICALS AND MATERIALS, BY PRODUCT, 2024 (% SHARE)
  135.   6.11 CHEMICALS AND MATERIALS, BY PRODUCT, 2024 TO 2035 (USD Million)
  136.   6.12 CHEMICALS AND MATERIALS, BY DISEASE, 2024 (% SHARE)
  137.   6.13 CHEMICALS AND MATERIALS, BY DISEASE, 2024 TO 2035 (USD Million)
  138.   6.14 BENCHMARKING OF MAJOR COMPETITORS
  139. 7 LIST OF TABLES
  140.   7.1 LIST OF ASSUMPTIONS
  141.     7.1.1
  142.   7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  143.     7.2.1 BY PRODUCT, 2025-2035 (USD Million)
  144.     7.2.2 BY DISEASE, 2025-2035 (USD Million)
  145.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  146.     7.3.1
  147.   7.4 ACQUISITION/PARTNERSHIP
  148.     7.4.1

Japan Chemicals and Materials Market Segmentation

Chemicals and Materials By Product (USD Million, 2025-2035)

  • Eylea
  • Lucentis
  • Beovu

Chemicals and Materials By Disease (USD Million, 2025-2035)

  • Macular Edema
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Age-Related Macular Degeneration

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓